Evaluation of glycated glucagon-like peptide-1(7-36)amide in intestinal tissue of normal and diabetic animal models

Biochimica et Biophysica Acta - General Subjects

Volumn 1569, Issue 1-3, 2002, Pages 75-80

  Mooney, Mark H ^a   Abdel Wahab, Yasser H A ^a   McKillop, Aine M ^a   O'Harte, Finbarr P M ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Diabetes; Glucagon like peptide 1; Glycation

Indexed keywords

CROSS REACTING ANTIBODY; EXOPEPTIDASE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; HYDROCORTISONE; STREPTOZOCIN; TISSUE EXTRACT;

AFFINITY CHROMATOGRAPHY; AGE; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME DEGRADATION; ENZYME INACTIVATION; EVALUATION; GLYCOSYLATION; HALF LIFE TIME; HYPERGLYCEMIA; IMMUNOREACTIVITY; INTESTINE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; OBESITY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; RADIOIMMUNOASSAY; TISSUE;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; GLYCOSYLATION; HYDROCORTISONE; INTESTINE, SMALL; MICE; MICE, OBESE; ORGAN SIZE; PEPTIDE FRAGMENTS; RATS;

ANIMALIA;

EID: 0037081765     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-4165(01)00237-9     Document Type: Article

References (46)

1. Contributions a l'etude des variations physiologiques de la secretion interne du pancreas: Relation entre les secretions externe et interne du pancreas
2. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations
3. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal
4. Glucagon-like peptide-1(7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: Acute post-prandial and 24-h secretion patterns
5. Glucagonostatic and insulinotropic action of glucagon-like peptide 1-(7-36)amide
6. Truncated GLP-1 (proglucagon 78-107 amide) inhibits gastric and pancreatic functions in man
7. Characterization of high-affinity receptors for truncated glucagon-like peptide-1 in rat gastric glands
8. Distribution of pre-proglucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system
9. Presence of glucagon and glucagon-like peptide-1-(7-36)amide receptors in solubilized membranes of human adipose tissue
10. Characterization of glucagon-like peptide 1(7-36)amide receptors of rat lung membranes by covalent cross-linking
11. The effect of intensive treatment of diabetes on the development of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
12. Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease
13. Nonenzymatic glycosylation of macromolecules
14. Progressive changes in lens crystallin glycation and high-molecular-weight aggregate formation leading to cataract development in streptozotocin-diabetic rats
15. Effect of glycated collagen on proliferation of human smooth muscle cells in vitro
16. Nonenzymatic glycosylation of human serum alters its conformation and structure
17. Complications neuropathy, pathogenetic considerations
18. Glycation of rat sciatic nerve tubulin in experimental diabetes mellitus
19. 'Glycated' osteocalcin in human and bovine bone
20. Structure of hemoglobin Alc: Nature of the N-terminal β chain blocking group
21. Evidence for an increase in glycation of IgG in diabetic patients
22. Glycated immunoglobulin M in diabetic patients
23. Glycation of insulin in the islets of Langerhans of normal and diabetic animals
24. Inactivation of glucose-6-phosphate dehydrogenase by glycation
25. In vivo glycation of aldehyde reductase, a major 3-deoxyglucosone reducing enzyme: Identification of glycation sites
26. Glycation (non-enzymic glycosylation) inactivates glutathione reductase
27. Inactivation of Cu, Zn-superoxide dismutase by in vitro glycosylation and in erythrocytes of diabetic patients
28. Models for testing new hypoglycaemic drugs
29. Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation
30. Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells
31. N-terminally modified glucagon-like peptide-1(7-36)amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo
32. N-terminally glycated gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity
33. Effects of glycated and non-glycated GLP-1(7-36)amide on glucose metabolism in muscle
34. Glycation of glucagon-like peptide-1(7-36)amide: Characterization and impaired action on rat insulin secreting cells
35. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice
36. Glycation of insulin in the islets of Langerhans of normal and diabetic animals
37. Determination of glucose by an automatic analyser
38. Incretin hormone expression in the gut of diabetic mice and rats
39. Isolation and characterisation of GLP-1 7-36 amide from rat intestine: Elevated levels in diabetic rats
40. Tissue-specific differences in the levels of proglucagon-derived peptides in streptozotocin-induced diabetes
41. Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice
42. The enteroinsular axis in models of hyperinsulinaemic and hypoinsulinaemic diabetes
43. Neuroendocrine peptides of the gastrointestinal tract of an animal model of human type 2 diabetes mellitus
44. Production and characterisation of specific antibodies for evaluation of glycated insulin in plasma and biological tissues
45. 7-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice
46. On the treatment of diabetes mellitus with glucagon-like peptide-1